SCHEMBL5761950

SCHEMBL5761950

Cc1cccc(CNS(=O)(=O)c2ccc(Cc3ccc4oc(=O)cc(C(F)(F)F)c4c3)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.48
CYP19A1 P11511 4/20 0.46
TP53 P04637 2/20 0.44
POLB P06746 2/20 0.44
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.41
CYP1A2 P05177 4/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
CYP3A4 P08684 3/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP2C19 P33261 2/20 0.40
NAMPT P43490 1/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762259 0.91 ALDH1A1 (0.49) ARCYP19A1GAACYP1A2CYP1A1
SCHEMBL5860408 0.89 GAA (0.46) ARCYP19A1TP53POLBMAPT
SCHEMBL5861496 0.89 CYP19A1 (0.46) ARCYP19A1TP53POLBMAPT
SCHEMBL5763003 0.88 CYP19A1 (0.48) ARCYP19A1TP53POLBMAPT
SCHEMBL5762929 0.86 HDAC4 (0.46) ARPOLBMAPTGAACYP1A2
SCHEMBL5761054 0.85 CA1 (0.46) ARCYP19A1TP53POLBMAPT
SCHEMBL5761672 0.85 MEN1 (0.47) ARCYP19A1POLBGAACYP1A2
SCHEMBL5760730 0.85 AR (0.41) ARCYP19A1GAACYP1A2CYP1A1
SCHEMBL5759332 0.84 IDO1 (0.46) MAPTALDH1A1CYP2C19KDM4EMEN1
SCHEMBL5762538 0.84 AR (0.51) ARCYP19A1TP53POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT AR 1/4885CYP19A1 5/4885TP53 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.